{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:24:49Z","timestamp":1789604689849,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40257-019-00446-6","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T19:48:53Z","timestamp":1558554533000},"page":"593-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis"],"prefix":"10.1007","volume":"20","author":[{"given":"Dee Anna","family":"Glaser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Nast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Werschler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Mamelok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Quiring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Drew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,20]]},"reference":[{"key":"446_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00403-016-1697-9","volume":"308","author":"J Doolittle","year":"2016","unstructured":"Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308:743\u20139.","journal-title":"Arch Dermatol Res"},{"key":"446_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13555-016-0148-z","volume":"7","author":"DA Grabell","year":"2017","unstructured":"Grabell DA, Hebert AA. Current and emerging medical therapies for primary hyperhidrosis. Dermatol Ther (Heidelb). 2017;7:25\u201336.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"446_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1098-3015(10)63957-5","volume":"6","author":"M Naumann","year":"2003","unstructured":"Naumann M, Hamm H, Spalding JR, Kowalski J, Lee J. Comparing the quality of life effects of primary focal hyperhidrosis to other dermatological conditions as assessed by the Dermatology Life Quality Index (DLQI). Value Health. 2003;6:242.","journal-title":"Value Health."},{"key":"446_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jaad.2003.12.040","volume":"51","author":"DR Strutton","year":"2004","unstructured":"Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol. 2004;51:241\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"446_CR5","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1111\/j.1468-3083.2012.04630.x","volume":"27","author":"MA Alvarez","year":"2013","unstructured":"Alvarez MA, Ruano J, Gomez FJ, Casas E, Baamonde C, Salvatierra A, et al. Differences between objective efficacy and perceived efficacy in patients with palmar hyperhidrosis treated with either botulinum toxin or endoscopic thoracic sympathectomy. J Eur Acad Dermatol Venereol. 2013;27:e282\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"446_CR6","first-page":"392","volume":"17","author":"DA Glaser","year":"2018","unstructured":"Glaser DA, Hebert A, Pieretti L, Pariser D. Understanding patient experience with hyperhidrosis: a national survey of 1,985 patients. J Drugs Dermatol. 2018;17:392\u20136.","journal-title":"J Drugs Dermatol"},{"key":"446_CR7","unstructured":"Qbrexza (glycopyrronium) cloth, 2.4%, for topical use [prescribing information]. Menlo Park (CA): Dermira, Inc.; 2018."},{"key":"446_CR8","unstructured":"International Hyperhidrosis Society. Hyperhidrosis treatment algorithms. 2018. Available from: \n                    https:\/\/www.sweathelp.org\/treatments-hcp\/clinical-guidelines\/hyperhidrosis-treatment-algorithms.html\n                    \n                  . Accessed 8 Nov 2018."},{"issue":"1","key":"446_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaad.2018.07.002","volume":"80","author":"DA Glaser","year":"2019","unstructured":"Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok R, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019;80(1):128\u201338.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"446_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40257-018-0395-0","volume":"20","author":"DM Pariser","year":"2019","unstructured":"Pariser DM, Hebert AA, Drew J, Quiring J, Gopalan R, Glaser DA. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient reported outcomes from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Am J Clin Dermatol. 2019;20(1):135\u201345.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"446_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/pde.13723","volume":"36","author":"AA Hebert","year":"2019","unstructured":"Hebert AA, Glaser D, Green L, Werschler WP, Forsha DW, Drew J, et al. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: post hoc analysis of efficacy and safety findings by age from two phase 3 randomized controlled trials. Pediatr Dermatol. 2019;36(1):89\u201399.","journal-title":"Pediatr Dermatol"},{"issue":"5 Suppl.","key":"446_CR12","first-page":"S16","volume":"11","author":"DA Glaser","year":"2018","unstructured":"Glaser DA, Hebert AA, Fehnel S, DiBenedetti D, Nelson L, Drew J, et al. Confirmatory psychometric evaluation of the Axillary Sweating Daily Diary: a validated patient-reported outcome measure to assess axillary hyperhidrosis sweating severity [abstract]. J Clin Aesthet Dermatol. 2018;11(5 Suppl.):S16\u20137.","journal-title":"J Clin Aesthet Dermatol."},{"key":"446_CR13","first-page":"908","volume":"33","author":"N Solish","year":"2007","unstructured":"Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33:908\u201323.","journal-title":"Dermatol Surg"},{"key":"446_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"446_CR15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1080\/09546634.2017.1309347","volume":"28","author":"JE Sammons","year":"2017","unstructured":"Sammons JE, Khachemoune A. Axillary hyperhidrosis: a focused review. J Dermatol Treat. 2017;28:582\u201390.","journal-title":"J Dermatol Treat."},{"issue":"Suppl. 8","key":"446_CR16","first-page":"S26","volume":"5","author":"DR Staskin","year":"2003","unstructured":"Staskin DR. Transdermal systems for overactive bladder: principles and practice. Rev Urol. 2003;5(Suppl. 8):S26\u201330.","journal-title":"Rev Urol."},{"key":"446_CR17","unstructured":"Hebert AA, Glaser DA, Green L, Werschler WP, Forsha DW, Drew J, et al., editors. Short- and long-term efficacy and safety of glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: post hoc pediatric subgroup analyses from the phase 3 studies. In: Oral presentation at the 27th international congress of the European academy of dermatology and venereology; 12\u201316 September, 2018; Paris."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00446-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-019-00446-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00446-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T23:21:27Z","timestamp":1589844087000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-019-00446-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,20]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1007\/s40257-019-00446-6","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,20]]},"assertion":[{"value":"20 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was sponsored and funded by Dermira, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dee Anna Glaser is an investigator for Allergan, Galderma, ATACAMA, Brickell Biotech, Inc., Dermira, Inc., Evolus, and Sienna Biopharmaceuticals, Inc. and a consultant for Dermira, Inc. William P. Werschler is a consultant and investigator for Dermira, Inc. Adelaide A. Herbert is a consultant for Dermira, Inc. and an employee of the UTHealth McGovern Medical School, which received compensation from Dermira, Inc. for study participation. Alexander Nast is an employee of Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, which received compensation from Dermira, Inc. for study participation; he was an advisory board member for Boehringer Ingelheim, carried out educational activities for Bayer and Novartis, and received research grants from Eli Lilly and Company, Pfizer, GSK, Plc., and MEDA. Lawrence Green is an investigator for Brickell Biotech, Inc. and an advisory board member and investigator for Dermira, Inc. Richard D. Mamelok is a consultant for Dermira, Inc. John Quiring is an employee of QST Consultations. Janice Drew is an employee of Dermira, Inc. David M. Pariser is a consultant and investigator for Brickell Biotech, Inc., Celgene Corporation, Dermira, Inc., LEO Pharma US, Novartis Pharmaceuticals, Promius Pharmaceuticals, Regeneron, and Valeant Pharmaceuticals International, a consultant for ATACAMA, Biofrontera AG, DUSA Pharmaceuticals, Inc., Sonofi, TDM SurgiTech, Inc., and TheraVida, and an investigator for Abbott Laboratories, Amgen, Asana Biosciences, Dermavant Sciences, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A\/S, Ortho Dermatologics, Peplin Inc., Pfizer Inc., Photocure ASA, and Stiefel (as GSK company).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ARIDO open-label extension study was conducted in the USA and Germany. The trial protocol and informed consent forms were approved by local institutional review boards or independent ethics committees on 10 August, 2015, and the first patient was enrolled on 27 August, 2015. The trial was registered on ClinicalTrials.gov on 18 September, 2015 (NCT02553798) and was carried out in accordance with Good Clinical Practice and the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}